MRM Health Secures FDA IND Clearance to Launch its Phase IIb Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MRM Health NV announced that the US FDA has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-ulcerative colitis Phase IIb clinical trial in patients with mild-to-moderate ulcerative colitis